What are the best applications of AI in the physical world for Biotechnology and Medical Instruments?

Best applications: AI embedded in expensive physical workflows

As of 11 September 2026, 14:53 UTC, imaging offers the clearest near-term commercialization case in the supplied evidence; autonomous laboratories and bioprocess control offer substantial longer-term potential. Digital pathology and surgical AI assistance are promising, but their incremental AI economics remain less established.

The investment test is not model sophistication. It is whether sensing, interpretation and action improve throughput, yield, accuracy or utilization—and whether vendors capture those gains through equipment, software, services or consumables.

1. Autonomous laboratories and bioprocess control

The goal is a closed loop: AI proposes experiments, robots execute them, instruments measure results, and subsequent actions adapt. Thermo Fisher’s NVIDIA collaboration targets connected instruments, laboratory infrastructure and data, progressively increasing automation. This is a development roadmap, not evidence of broadly deployed autonomous laboratories. [1]

Promising targets include high-throughput screening, cell-line and enzyme engineering, formulation optimization and in-line bioprocess monitoring. Batch-release analytics could also benefit, but automated release decisions require particularly rigorous validation. Potential savings come from more experiments per scientist, reduced waste and fewer failed batches.

Danaher invested more than $2 billion over several years in bioprocessing capacity, including digital and AI capabilities—not $2 billion exclusively in AI. Its 2025 revenue was $24.6 billion, operating cash flow $6.4 billion, and non-GAAP free cash flow $5.3 billion. These establish franchise scale, not AI-generated returns. Thermo Fisher’s annual-report materials describe annual revenue above $45 billion, without clearly identifying the measurement period in the supplied excerpt. [2] [3] [4]

The cited bioprocess review argues that hardware maturity is no longer the primary bottleneck. Interoperability, trustworthy data and validated control remain critical. Adoption is most plausible in repetitive, data-rich workflows where savings exceed integration costs. [5]

2. Medical imaging and scan guidance

AI reconstruction, automated analysis and acquisition guidance connect directly to measurable scanner productivity. Siemens Healthineers describes efforts to improve image quality while shortening scans. GE HealthCare’s 2025 annual report cites 115 AI-enabled FDA authorizations and ultrasound guidance providing real-time acquisition instructions. [6] [7]

Authorization permits marketing within the relevant regulatory scope; it does not establish superior outcomes, revenue or hospital return on investment. [8]

Faster scans and fewer repeats can increase output, but only if staffing, scheduling and demand do not become the binding constraints. Vendors may monetize upgrades and service contracts; hospitals must absorb training and workflow costs.

Siemens Healthineers reported FY2025 revenue of €23.375 billion, including €13.182 billion in Imaging. Its installed base supports significant recurring service and spare-parts revenue. AI can reinforce that established business rather than requiring a standalone software franchise. [6]

3. Digital pathology

Glass slides must first become digital images. Labcorp’s Roche collaboration proposes deploying FDA-cleared VENTANA DP 600 and DP 200 scanners, enabling digital diagnosis and supporting future AI integration. [9]

Near-term opportunities are remote review, image sharing and better utilization of scarce pathology expertise. Longer-term applications include triage, quantification and decision support. Scanner deployment is not proof of AI adoption or profitability. Storage, integration, validation across staining protocols and populations, liability, reimbursement and pathologist acceptance can constrain returns.

4. Robotic surgery and procedural assistance

Robotics is not inherently AI. Intuitive Surgical provides an established physical platform onto which AI assistance may be added. Its 2025 report describes acquiring a developer of integrated robotics and AI solutions targeting accuracy and efficiency. [10]

Intuitive reported approximately $10.1 billion of 2025 revenue, up 21%, with recurring instruments-and-accessories sales. Those platform economics—not separately demonstrated AI monetization—anchor the investment case. Installed systems and training can support switching costs, but do not guarantee pricing power. AI-specific revenue, margins and utilization gains are not established in the supplied evidence. [11]

Investment implications

• Danaher (NYSE: DHR): direct biotechnology-workflow exposure; monitor bioprocess demand and customer productivity gains versus vendor pricing.

• Thermo Fisher (NYSE: TMO): broad instruments, consumables and services exposure; breadth also dilutes near-term AI earnings sensitivity.

• Siemens Healthineers (Xetra: SHL) and GE HealthCare (Nasdaq: GEHC): direct imaging exposures; hospital budgets, reimbursement, product execution and currency remain important.

• Intuitive Surgical (Nasdaq: ISRG): recurring procedural economics first, AI upside second; procedure growth and utilization must support valuation.

These are application-linked exposures, not an unconditional buy ranking.

Valuation

GE HealthCare and Siemens Healthineers have lower reported P/Es in these observations. That is not proof of undervaluation: growth, leverage, accounting and business mix differ. The supplied extracts do not establish a common trailing-earnings methodology or timestamp, limiting comparability.

What would invalidate the thesis?

The thesis weakens if workflow savings fail to materialize, validation costs exceed benefits, adoption stalls, or competition transfers most gains to customers. Monitor scan times, repeat rates, batch failures, procedure duration, installed-system utilization, software attachment, recurring service and consumables growth, and disclosed AI margins. Value established franchises first; credit AI upside when it changes purchasing behavior or recurring revenue.